Brussels   |  

Europe’s healthcare biotech ‘stars’: How can we nurture them?


Healthcare biotech is a diverse sector, with 2,000 companies in Europe ranging from large multinational enterprises – with global annual sales exceeding €10 billion and annual research and development (R&D) expenditures of €1-€4 billion – to much smaller enterprises with fewer than ten employees and only grant-based income. It also includes hundreds of thousands of talented researchers, doctors and healthcare workers – all striving to push the frontiers of medical know-how.

To stimulate the discussion, we will be joined by two of the sector’s stars, Edwin Moses, CEO of Ablynx of Ghent and Jörn Aldag, CEO of Uniqure of Amsterdam, to hear their stories from the  ‘front lines’ of healthcare biotech. We will discuss with them how they got started, what obstacles they had to overcome, and what policy prescriptions their experiences might suggest. Other featured guests include Didier Schmitt, Scientific Adviser & Foresight Coordinator, European Commission and Rudolf Strohmeier, Deputy Director General, DG Research and Innovation, European Commission.

This event is by invitation only. Please contact shane.mccollam@sciencebusiness.net  if you are interested in participating.

Event pack
Photos

Programme
Programme

18:30 - Welcome & introduction by Richard L. Hudson, CEO & Editor, Science|Business

18:35 - Europe’s Healthcare Biotech Stars

  • Case study I: Jörn Aldag, uniQure, on better, faster procedures for getting new
    medicines to market
  • Case study II: Edwin Moses, Ablynx, on the biotech healthcare value chain

18:55 - Moderated discussion

Opening statements:

  • Dainius Pavalkis, Minister of Education and Science of the Republic of Lithuania
  • Rudolf Strohmeier, Deputy Director-General, DG RTD, European Commission
  • Emmanuel Chantelot, Chairman of EuropaBio’s Healthcare Biotechnology Council

Moderator: Richard L. Hudson, CEO & Editor, Science|Business

19:30 - Dinner debate

Co-moderated by:

  • Richard L. Hudson, CEO & Editor, Science|Business
  • Nathalie Moll, Secretary General, EuropaBio

Opening statements: The view from the Parliament:

  • Vicky Ford, Member, European Parliament
  • Philippe De Backer, Member, European Parliament
Speakers
Speakers
Jörn Aldag
CEO, uniQure
Thomas Allvin
Health Counsellor, Permanent Representation of Sweden to the EU
Philippe De Backer
Member, European Parliament
Binah Baum
Co-Founder and CEO, Alma Bio Therapeutics
Emmanuel Chantelot
Head of International Government Relations and Public Affairs, Shire
Anaïs Le Corvec
International Project Manager, Vall d’Hebron Institut de Recerca (VHIR)
Francis P. Crawley
Executive Director, Good Clinical Practice Alliance— Europe
Vicky Ford
Member, European Parliament
Eva Grut-Aandahl
Head of European Government Affairs/EU Representation Office, Pfizer
Svens Henkuzens
Health Attaché, Permanent Representation of the Republic of Latvia to the EU